CVS Pharmacy announced on Friday that more than 9,800 of its pharmacies across the US has been stocked with the new Shingrix vaccine for patients.
The company said the new vaccine was reportedly licensed by the US Food and Drug Administration (FDA) in 2017 and is now recommended by the Centers for Disease Control and Prevention (CDC).
According to the company, healthy adults age 50 and older are recommended to get two doses of Shingrix, two to six months apart, to prevent shingles and reduce the course and severity of the disease. About 99% of people ages 50 and older are at risk of getting shingles, a painful rash that is also known as herpes zoster, in their lifetime. There are an estimated one million cases of shingles each year in the US.
In conjunction, many health insurance plans will cover the company's new vaccine, including Medicare Part D. Patients are encouraged to contact their insurance provider to determine if and when their individual plan will cover the Shingrix vaccine.
CVS Pharmacy is a retail pharmacy with over 9,800 locations across the US and the retail division of CVS Health (NYSE: CVS).
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma